Tag Archives: Oren Livnat

H.C. Wainwright Believes Antares Pharma (NASDAQ: ATRS) Won’t Stop Here

H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Antares Pharma (ATRS – Research Report) today and set a price target of $4.50. The company’s shares closed yesterday at $3.61, close to its 52-week high of $3.93. Livnat said:

H.C. Wainwright Keeps a Buy Rating on Novan Inc (NOVN)

In a report released today, Oren Livnat from H.C. Wainwright maintained a Buy rating on Novan Inc (NOVN – Research Report), with a price target of $8. The company’s shares closed yesterday at $2.62, close to its 52-week low of

H.C. Wainwright Believes BioDelivery (NASDAQ: BDSI) Won’t Stop Here

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on BioDelivery (NASDAQ: BDSI), with a price target of $5. The company’s shares opened today at $4, close to its 52-week high of $4.09. Livnat said:

Corium (CORI) Receives a Buy from H.C. Wainwright

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Corium (NASDAQ: CORI), with a price target of $13. The company’s shares closed on Friday at $8.65. Livnat noted: “Our $13 12-month target is based

H.C. Wainwright Sticks to Their Buy Rating for BioDelivery (BDSI)

H.C. Wainwright analyst Oren Livnat maintained a Buy rating on BioDelivery (NASDAQ: BDSI) today and set a price target of $4. The company’s shares closed yesterday at $2.90. According to TipRanks.com, Livnat has currently no stars on a ranking scale

H.C. Wainwright Remains a Hold on Jazz Pharmaceuticals (JAZZ)

H.C. Wainwright analyst Oren Livnat reiterated a Hold rating on Jazz Pharmaceuticals (NASDAQ: JAZZ) today and set a price target of $167. The company’s shares closed yesterday at $175.58, close to its 52-week high of $184. Livnat observed: “We highlighted